RNS Number: 0310 G Evgen Pharma PLC 18 July 2019. The Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.. RNS is approved by the Financial...
Evgen Pharma Plc (EVG.L) Announced that the company will hold its Annual General Meeting (AGM) later today. The company's Chairman, Barry Clare will be making the statement at the AGM. A short presentation will be given to shareholders at the AGM. The presentation will contain no new material information and will be made available later today on the company’s website.
RNS Number: 9072 F Evgen Pharma PLC 18 July 2019. "Further anticipated near-term news flow includes the announcement of secondary data and additional insights from the metastatic breast cancer trial at the ESMO 2019 conference in Barcelona in the early autumn.. "The £5 m equity placing completed earlier this year has given us the financial resources to support...
Evgen Pharma Plc (EVG.L) Announced that the company and its lead product, SFX-01, are featured in a recently published paper entitled "Neuroprotective Role of the Nrf2 Pathway in Subarachnoid Haemorrhage and Its Therapeutic Potential". SFX-01 is the company's synthetic formulation of stabilised sulforaphane (SFN). The review paper, in the journal "Oxidative Medicine and Cellular Longevity", is co-authored by consultant neurosurgeon Diederik Bulters, the company’s principal investigator on the Phase IIb trial in subarachnoid haemorrhage at University Hospital Southampton.
RNS Number: 1018 D Evgen Pharma PLC 24 June 2019. Lead product SFX-01 featured in SAH review paper. Evgen Pharma plc, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that Evgen and its lead product, SFX-01, are featured in a recently published paper entitled "Neuroprotective Role of the Nrf2...
RNS Number: 7659 C Evgen Pharma PLC 19 June 2019. The Company's AGM will be held at 2.00 pm at the offices of RSM UK Audit LLP, 3 Hardman Street, Manchester M3 7 HF on Thursday 18 July 2019.. The Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It...
Evgen Pharma Plc (EVG.L) Announced, in its final results for the year ended 31 March 2019, the loss before tax stood at £3.12 million, compared to loss of £3.03 million reported in the previous year. The basic loss per share stood at 2.74p compared to loss per share of 3.28p reported in the previous year. The company’s cash and equivalents stood at £2.03 million
RNS Number: 0244 C Evgen Pharma PLC 13 June 2019 For immediate release 13 June 2019. Final Results for the year ended 31 March 2019. Evgen Pharma plc, the clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces its final results for the year ended 31 March 2019..
Evgen Pharma Plc (EVG.L) Announced that it will publish its preliminary results for the year ended 31 March 2019 on 13 June 2019.
RNS Number: 7450 B Evgen Pharma PLC 11 June 2019. The Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.. RNS is approved by the Financial...
RNS Number: 8817 Z Evgen Pharma PLC 22 May 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 6039 Z Evgen Pharma PLC 21 May 2019 For immediate release. Share option exercise and issue of equity. Accordingly, the Company has issued and allotted 321,600 new ordinary shares of 0.25 pence each.
RNS Number: 5811 Y Evgen Pharma PLC 09 May 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 5094 Y Evgen Pharma PLC 09 May 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 3855 Y Evgen Pharma PLC 08 May 2019 Evgen Pharma plc. Evgen Pharma plc, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that at the Company's General Meeting held earlier today, all of the resolutions tabled at the meeting were duly passed. This completes the Placing to raise £5...
RNS Number: 2599 X Evgen Pharma PLC 26 April 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 2589 X Evgen Pharma PLC 26 April 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9637 W Evgen Pharma PLC 24 April 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9633 W Evgen Pharma PLC 24 April 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 8326 W Evgen Pharma PLC 23 April 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Evgen Pharma Plc
EVG.L
Evgen Pharma Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    98.99M

Classification

Market Indices-

Locations

HQ
Liverpool Science Park
Innovation Centre 2
146 Brownlow Hill
Liverpool
L3 5RF
Watchlist